Royal Sonesta Hotel Boston
5 Cambridge Parkway
Cambridge, MA 02142
Directions

Click here to register online
or
Contact Judy Truglia
By email: jtruglia@mbbp.com
By phone: 781-622-5930

Please register by February 27.
Space is limited and may be filled quickly

Networking Reception
Enjoy light hors d'oeuvres, beer & wine

Dick Meijer (bio)
Vice President – General Manager of Canada, Australasia, Sub-Saharan Africa and the Indian Subcontinent
Genzyme Corporation

One of the world's foremost biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in Boston in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $2 billion and more than 8,500 employees in locations spanning the globe. www.genzyme.com

Daniel J. Moore (bio)
President, International Distributor Management
Boston Scientific Corporation

For more than 25 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. Today, with more than 29,000 employees and 26 manufacturing, distribution and technology centers, Boston Scientific remains true to its original mission. As a market leader in less-invasive medical devices delivering more than 15,000 products to clinicians in over 45 countries, Boston Scientific works every day to build the knowledge, processes and infrastructure it needs to identify opportunities, address new disease areas and support clinicians in advancing the practice of health care around the world. www.bostonscientific.com

Richard W. Pascoe (bio)
Vice President and Chief Commercial Officer
ARIAD Pharmaceuticals, Inc.

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity, which may be useful in treating certain diseases. www.ariad.com

Jeffrey P. Somers (bio)

Shannon S. Zollo (bio)

Members, Morse, Barnes-Brown & Pendleton, P.C.

Dick Meijer is a Dutch national and has been relocated to Genzyme’s head office in Cambridge, US in April 2002 to assume the position of Vice President – General Manager of the Asia Pacific region that included China, Korea, Taiwan, Hong Kong, South East Asia and Australasia.
In the beginning of 2007 he was appointed in his current position.

In 1991, Dick Meijer was co-founder of Genzyme Europe BV., in the Netherlands. Before his relocation to the United States, he served as Vice President – General Manager for Scandinavia, Finland, Benelux, Greece and Portugal and was based at Genzyme European Headquarters in the Netherlands.

In that role, he provided leadership in the European introduction of Ceredase and Cerezyme for the treatment of patients suffering from Gaucher disease.

Additional responsibilities included market development in the Central and Eastern European countries for almost 4 years. He is the co-founder of the Dutch Society for Medical Biotechnology Industry, Biofarmind and was chairman of the working group on Orphan Drugs in Biofarmind.

He is member of the Board of Directors of various Genzyme subsidiaries around the world. He studied International Management at the CEDEP, Centre d’Education d’European Permanente in Fontainebleau in France and INSEAD in Singapore.

He has more than 30 years experience in the health care industry i.e., medical, pharmaceutical and biotechnology with a sound track record for commercializing medical, therapeutic and innovative biotechnology products, as well as building local country infrastructure, partnerships, distributions agreements in Europe and Asia.

Before joining Genzyme in 1991, Dick Meijer served in various sales, marketing and senior management positions with GD Searle, Boehringer Mannheim and Baxter in the Netherlands.
(Back to list of panelists)

Daniel J. Moore, President of International Distributor Management
Boston Scientific Corporation

Dan joined Boston Scientific in 1989 as Territory Manager and most recently was Vice President and General Manager for Boston Scientific's Vascular Surgery business. In this role, he led a cross-functional team to restore growth to this franchise while advancing Endovascular Aortic Stent Graft programs. Previously, he was Vice President of Marketing for Inter-Continental responsible for the Marketing program covering all businesses. In this role, he led the launch of the TAXUS® paclitaxel-eluting coronary stent system in the Inter-Continental markets. In addition, Dan has helped develop and facilitate Program for Advanced Leadership and Management (PALM) courses at Boston Scientific while also leading the Company's first high-impact team focusing on capital equipment.

Prior to Boston Scientific, Dan spent four years at Procter & Gamble where he held a variety of management and sales positions.

Dan has served on several industry boards, including the board of directors of TriVascular, Inc., and the International Society of Endovascular Specialists and currently serves on the board for Smiling Kids Charity.

Dan earned a B.A. from Harvard University and a M.B.A. with high honors from Boston University.
(Back to list of panelists)

Richard W. Pascoe, Vice President and Chief Commercial Officer
ARIAD Pharmaceuticals, Inc.

Richard Pascoe has served as ARIAD’s Chief Commercial Officer since November 2005. Prior to ARIAD, Mr. Pascoe served in numerous senior commercial positions at King Pharmaceuticals Inc. to include Senior Vice-President of King’s Neuroscience franchise, Vice President of Primary Care Sales, Vice President of International, and Vice-President of Hospital Sales.

Mr. Pascoe was Director of Marketing at Medco Research Inc. from 1999 to late 2000 when Medco was acquired by King. Prior to Medco Research, Mr. Pascoe was a Regional Sales Manager with COR Therapeutics from 1997 to 1999. From 1993 to 1997, Mr. Pascoe held positions at B. Braun Interventional as Regional Manager and Hospital Account Manager.

Mr. Pascoe is a 1986 graduate of the United States Military Academy and served as a commissioned officer in the United States Army from 1986 to 1991.
(Back to list of panelists)